Does the Theranos trial actually matter? Is the FDA coming unglued? And what can prescription data tell us about America?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Former Theranos CEO Elizabeth Holmes is finally headed to trial, and we discuss the case and why it might not be an open-and-shut conviction for prosecutors. Then, STAT Washington correspondent Nicholas Florko joins us to explain the latest upheaval at the FDA, which arrives just as the agency faces mounting pressure to speed up the review of Covid-19 vaccines. We also discuss the race to develop antivirals for SARS-CoV-2 and why the eyelash-growth business is booming.
For more on what we cover, here’s more on the Holmes trial; here’s the latest on the FDA; here’s the news on pandemic prescription data; here’s the story on antiviral trials; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].
Create a display name to comment
This name will appear with your comment